Kristina Harpe
Critical Care Medicine · Atlanta, GANPI 1497295083
Payments from drug & device makers
Across 66 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$286
- Lilly USA, LLC$173
- Shield Therapeutics Inc$141
- GSK$136
- AstraZeneca$70
- Astellas Pharma US Inc$64
- plus $426 from 16 others
What the payments were for
- Food & beverage$1,28199%
- Entertainment$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $286 |
| Lilly USA, LLC | 15 | $173 |
| Shield Therapeutics Inc | 6 | $141 |
| GSK | 3 | $136 |
| AstraZeneca | 4 | $70 |
| Astellas Pharma US Inc | 3 | $64 |
| Pfizer | 3 | $50 |
| Boston Scientific | 1 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Amgen | 2 | $32 |
| Mayne Pharma Commercial LLC | 1 | $31 |
| Exact Sciences | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Biotronik NRO, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $14 |
How this compares
$1,295 in reported general payments places this provider in the 70th percentile of 265 critical care medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $49,459 |
| JardianceEmpagliflozin | 28 | $40,875 |
| MounjaroTirzepatide | 16 | $32,281 |
| FarxigaDapagliflozin Propanediol | 23 | $31,102 |
| EliquisApixaban | 20 | $15,707 |
| GemtesaVibegron | 15 | $9,954 |
| LinzessLinaclotide | 11 | $8,756 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,966 |
| Celecoxib | 41 | $1,194 |
| Atorvastatin Calcium | 104 | $812 |
| Levothyroxine Sodium | 77 | $776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $719 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $470 |
| Ezetimibe | 17 | $446 |
| Gabapentin | 30 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $286 | $49,45927 claims |
| Boehringer IngelheimJardiance | $21 | $40,87528 claims |
| Lilly USA, LLCMounjaro | $173 | $32,28116 claims |
| AstraZenecaFarxiga | $70 | $31,10223 claims |
| PfizerEliquis | $50 | $15,70720 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $33 | $9,95415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Atlanta
- Ramzy RimawiAtlanta$72K
- Matthew SchmittAtlanta$32K
- Philip ForysAtlanta$11K
- Jeremy CourtneyAtlanta$8K
- Andre HolderAtlanta$6K
- Michael ConnorAtlanta$4K
- Matthew ThauAtlanta$4K
- Seema TekwaniAtlanta$3K
- Adam WebbAtlanta$3K
- Katie RattrayAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.